首页> 外文期刊>Cellular and molecular biology >PREFERENTIAL HIV-1 INTEGRATION SITES IN MACROPHAGES AND HIV-ASSOCIATED MALIGNANCIES.
【24h】

PREFERENTIAL HIV-1 INTEGRATION SITES IN MACROPHAGES AND HIV-ASSOCIATED MALIGNANCIES.

机译:在巨噬细胞和艾滋病毒相关的恶性肿瘤中首选HIV-1整合位点。

获取原文
获取原文并翻译 | 示例
           

摘要

HIV-infected individuals are at risk for developing certain types of cancers. While there are data to show that non-random HIV integration may occur, our goal was to identify preferential genomic sites where HIV integration might be targeted leading to oncogenesis. Initially, a linker-primer PCR strategy was used to identify HIV integration in isolated macrophages. Inverse-PCR was then used to analyze specimens from patients diagnosed with HIV-associated malignancies. From isolated macrophages, integration near a toll-like receptor on chromosome 4 was found. Necropsy tissues from 11 cases were analyzed with 1 tumor specimen found to have HIV integrated in chromosome 22q13.2 and within 300 kb of HSCBCIP1 (CAP-binding protein complex interacting homologue). Tumor-specific primers were then used to screen uninvolved tissue from the same patient, which did not amplify the site-specific region. This report demonstrates that in both an in vitro system and human malignant tissue, specific viral integration can be identified.
机译:感染了HIV的个体有患某些类型癌症的危险。尽管有数据显示可能会发生非随机的HIV整合,但我们的目标是确定可能以HIV整合为目标导致肿瘤发生的优先基因组位点。最初,使用引物-引物PCR策略来鉴定HIV在单个巨噬细胞中的整合。然后使用反向PCR分析来自诊断为与HIV相关的恶性肿瘤的患者的标本。从孤立的巨噬细胞中,发现整合到第4号染色体上的收费型受体附近。分析了11例患者的尸检组织,并分析了1个肿瘤标本,发现其HIV整合在22q13.2号染色体中以及HSCBCIP1(CAP结合蛋白复合物相互作用同源物)的300 kb以内。然后,使用肿瘤特异性引物筛选来自同一患者的未受累组织,该组织未扩增位点特异性区域。该报告表明,在体外系统和人类恶性组织中,都可以鉴定出特定的病毒整合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号